Moral Judgments and COVID-19 Vaccine Hesitancy
Whatever strategy you employ to encourage vaccinations, it is important to be respectful and empathize with your patient’s concerns and perspectives.
Uncategorized
Kitchen on Call: Well-Deserved Holiday Cocktails for the Busy Doctor
In the whirlwind of the holidays, especially after the year most docs have had, it’s important to take time to wind down and enjoy the season. Wrapping yourself in a favorite wool blanket, donning cozy loungewear and sitting by a fireplace (if you’re fortunate enough to have one) all help, but a winter cocktail can…
Risk of Stroke in Hospitalized SARS-CoV-2 Patients: A Meta-Analysis
Study authors conducted a multinational meta-analysis in SARS-CoV-2 patients to assess the risk of stroke relative to the general population and to identify risk factors of stroke.
Intrinsic Circadian Sleep-Wake Rhythm Disorders: Latest Guidance and Treatment
Melatonin and other melatonin receptor agonists have demonstrated efficacy in the treatment of circadian rhythm disorders in both pediatric and adult populations.
Hand-Hygiene Adherence Varies at Critical Points of Care
Healthcare workers were more likely to partake in hand-hygiene protocols after contaminating tasks vs critical tasks and before such tasks.
Machine Learning Predicts Noncalcified Coronary Burden in Psoriasis
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
Neurogenic Orthostatic Hypotension: Treatments
Treatment of Neurogenic Orthostatic Hypotension
Potential First-in-Class Treatment for Tourette Syndrome Gets Fast Track Status
The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).
Symdeko Approved to Treat Younger Cystic Fibrosis Patients
The Food and Drug Administration (FDA) has approved Symdeko (tezacaftor/ivacaftor and ivacaftor; Vertex Pharmaceuticals) for the treatment of patients aged ≥6 years with cystic fibrosis (CF) who are homozygous for the F508del mutation or who have at least 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor. Previously,…
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Uncategorized
Loading... 
Loading...